Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit.

[1]  R. Brooks,et al.  Evidence that expression of inducible nitric oxide synthase in response to endotoxin is augmented in atherosclerotic rabbits. , 1995, Circulation research.

[2]  A. Schmidt,et al.  Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. , 1995, The Journal of clinical investigation.

[3]  S. Jimi,et al.  Nonenzymatic glycation and extractability of collagen in human atherosclerotic plaques. , 1995, Atherosclerosis.

[4]  M. Cybulsky,et al.  Advanced Glycation Endproducts Promote Adhesion Molecule (VCAM-1, ICAM-1) Expression and Atheroma Formation in Normal Rabbits , 1995, Molecular medicine.

[5]  T. Koschinsky,et al.  Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[6]  G. Otto,et al.  Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. , 1995, The American journal of pathology.

[7]  T. Kodama,et al.  Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. , 1995, The American journal of pathology.

[8]  Yong Ming Li,et al.  Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Grundy,et al.  Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. Schmidt,et al.  Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  E. Friedman,et al.  Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure , 1994, The Lancet.

[12]  R. Cohen,et al.  Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[13]  Y. Zou,et al.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.

[14]  Julie H. Campbell,et al.  Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture. , 1994, Atherosclerosis.

[15]  R. Bucala,et al.  Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. , 1993, The American journal of pathology.

[16]  M. Huijberts,et al.  Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. , 1993, The Journal of clinical investigation.

[17]  A. Bowie,et al.  Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? , 1993, Atherosclerosis.

[18]  R. Bucala,et al.  Lipid advanced glycosylation: pathway for lipid oxidation in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[19]  T. Verbeuren,et al.  Evidence for induction of nonendothelial NO synthase in aortas of cholesterol-fed rabbits. , 1993, Journal of cardiovascular pharmacology.

[20]  T. Lyons,et al.  Glycation and oxidation: a role in the pathogenesis of atherosclerosis. , 1993, The American journal of cardiology.

[21]  M. Dominiczak,et al.  Collagen-linked fluorescence in human atherosclerotic plaques. , 1993, Atherosclerosis.

[22]  S. Krungkrai,et al.  Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Lyons.  Lipoprotein Glycation and Its Metabolic Consequences , 1992, Diabetes.

[24]  R. Bucala,et al.  Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. , 1992, The Journal of clinical investigation.

[25]  P. Tsao,et al.  Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. , 1992, The Journal of clinical investigation.

[26]  I. Laing,et al.  Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. , 1992, Atherosclerosis.

[27]  M. Gilcrease,et al.  Secretion of a chemotactic substance(s) by AGE-stimulated human monocytes. , 1992, Diabetes research and clinical practice.

[28]  M. Mcdaniel,et al.  Aminoguanidine, a Novel Inhibitor of Nitric Oxide Formation, Prevents Diabetic Vascular Dysfunction , 1992, Diabetes.

[29]  R. Bucala,et al.  Immunochemical detection of advanced glycosylation end products in vivo. , 1992, The Journal of biological chemistry.

[30]  W. Parmley,et al.  Effect of Lovastatin on Suppression and Regression of Atherosclerosis in Lipid‐Fed Rabbits , 1992, Journal of cardiovascular pharmacology.

[31]  S. Yagihashi,et al.  Effect of Aminoguanidine on Functional and Structural Abnormalities in Peripheral Nerve of STZ-Induced Diabetic Rats , 1992, Diabetes.

[32]  H. Hammes,et al.  Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[33]  G. Jerums,et al.  Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat , 1991, Diabetes.

[34]  K. Tracey,et al.  Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. , 1991, The Journal of clinical investigation.

[35]  S. Ogawa,et al.  Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[36]  L. Moldawer,et al.  Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor. , 1989, The Journal of clinical investigation.

[37]  H. Gerlach,et al.  Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties , 1989, The Journal of experimental medicine.

[38]  R. Klein,et al.  Enhancement of Platelet Aggregation by Low-Density Lipoproteins From IDDM Patients , 1988, Diabetes.

[39]  R. Dean,et al.  Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. , 1988, The Biochemical journal.

[40]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[41]  A. Cerami,et al.  Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.

[42]  A. Cerami,et al.  Nonenzymatic Glycosylation Products on Collagen Covalently Trap Low-Density Lipoprotein , 1985, Diabetes.

[43]  A. Albers,et al.  Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol. , 1985, Clinical chemistry.

[44]  J L Witztum,et al.  Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. Morel,et al.  Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. , 1983, Journal of lipid research.

[46]  J L Witztum,et al.  Nonenzymatic Glucosylation of Low-Density Lipoprotein Alters Its Biologic Activity , 1982, Diabetes.

[47]  P. D. Henry,et al.  Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. , 1981, The Journal of clinical investigation.

[48]  L.,et al.  Glucosylation of human collagen in aging and diabetes mellitus. , 1980, The Journal of clinical investigation.

[49]  G. Mills,et al.  The distribution and composition of serum lipoproteins in eighteen animals. , 1971, Comparative biochemistry and physiology. B, Comparative biochemistry.

[50]  W. Severs,et al.  A specific and sensitive assay for aminoguanidine: its application to a study of the disposition of aminoguanidine in animal tissues. , 1969, The Journal of pharmacology and experimental therapeutics.

[51]  J. Strong,et al.  Technics for studying atherosclerotic lesions. , 1958, Laboratory investigation; a journal of technical methods and pathology.